Jessica Ann Walsh
Rating: 4.9 of 5
( out of 80 reviews )

Jessica Ann Walsh, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Rheumatology, Area E
50 N Medical Dr
Salt Lake City , UT 84132
801-581-7724
Get Directions

  • Jessica Walsh, MD, is an Associate Professor at the University of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.



    Walsh received her Medical Degree and Rheumatology training from the University of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Rheumatology)

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 80 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    December 07, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Excellent doctor, have been with her many years

    October 25, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Dr Walsh is excellent to work with. I HIGHLY recommend her.

    October 05, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    She is very friendly and has a great sense of humor.

    August 05, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Dr. Walsh is a superlative rheumatologist!

    June 21, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    She is great. She listens and cares.

    June 19, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Dr Walsh has given me great care and advice.

    June 02, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    She has always provided me with positive results.

    May 19, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    I really appreciated her thoroughness and willingness to spend the time to understand everything that was going on with my health. I really appreciated it!!!

    April 25, 2025
    UNIVERSITY HOSPITAL
    Rating: 5 out of 5

    Dr. Walsh is an excellent physician, she has communicated very clearly and makes sure I understand my options. Her expertise and leadership in developing the specialty clinic at U of U Rheumatology adds a great deal of value to our healthcare community.

  • Jessica Walsh, MD, is an Associate Professor at the University of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.



    Walsh received her Medical Degree and Rheumatology training from the University of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor
    Dermatology -Adjunct Associate Professor
    Academic Divisions Rheumatology
    Board Certification
    American Board of Internal Medicine (Sub: Rheumatology)

    Education history

    Graduate Training Clinical Investigation - University of Utah M.S.C.I
    Fellowship Rheumatology - University of Utah Fellow
    Chief Resident Internal Medicine - University of Utah Chief Resident
    Residency Internal Medicine - University of Utah Resident
    Internship Internal Medicine - University of Utah Intern
    Professional Medical Medicine - University of Utah M.D.
    Graduate Training Business Administration - Boise State University M.B.A.
    Undergraduate Biology - Whitman College B.A.

    Selected Publications

    Journal Article

    1. Hernndez C, Schlesinger N, Rojas J, Walsh JA, Braaten TJ, Kunkel GA, Jones M, Sauer BC, Facelli J, Cannon GW, Lebiedz-Odrobina D (2025). COVID-19 Vaccination is not Associated with the Development of Idiopathic Inflammatory Myositis in U.S. Veterans. Arthritis Care Res (Hoboken). (Read full publication)
    2. Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF (2025). Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors. Adv Ther. (Read full publication)
    3. Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF (2025). On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. Rheumatol Ther. (Read full publication)
    4. OSullivan ML, Cannon GW, Sauer BC, Rojas J, Kunkel GA, Walsh JA, Patel S, Roul P, Baker JF, England BR, Mikuls TR, Braaten TJ (2025). Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs). Arthritis Care Res (Hoboken). (Read full publication)
    5. Walsh JA, Saffore CD, Ye X, Patel M, Biljan A, Vora J, Truman I, Edwards M, Milligan G, Ostor A (2025). Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe. Rheumatol Ther. (Read full publication)
    6. Singla S, Pennington SR, Hwang ST, Walsh JA (2025). World Café Report From the GRAPPA 2024 Annual Meeting and Trainee Symposium: Exploring GRAPPA's Future Priorities. J Rheumatol. (Read full publication)
    7. Dubreuil M, Walsh JA, Deodhar A, Gensler LS, Curtis JR, Welby S, Pilipczuk O, Beaty S, Mrup MF, Taieb V, Anjohrin S (2025). Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations. Pharmacoepidemiol Drug Saf, 34(9), e70197. (Read full publication)
    8. Merola JF, Welby S, Roque H, Song J, Pilipczuk O, Lu C, Walsh JA (2025). Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns. J Manag Care Spec Pharm, 31(8), 808-821. (Read full publication)
    9. Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie A (2025). Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort. Arthritis Care Res (Hoboken), 77(8), 1007-13. (Read full publication)
    10. Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA (2025). Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials, 26(1), 96. (Read full publication)
    11. Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh JA (2024). Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Adv Ther, 42(2), 734-751. (Read full publication)
    12. Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A (2025). Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium. Ann Rheum Dis, 84(2), 253-261. (Read full publication)
    13. Gossec L, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O, Cella D (2024). Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial. Rheumatol Ther, 12(1), 85-98. (Read full publication)
    14. Wang V, Walsh J, Zell J, Verrilli LE, Letourneau J, Johnstone EB, Allen-Brady K, Welt CK (2024). Autoimmune Disease is Increased in Women with Primary Ovarian Insufficiency. J Clin Endocrinol Metab, 110(8), e2614-2620. (Read full publication)
    15. Carroll C, Adalsteinsson JA, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Erratum: Measuring Psoriasis Severity at Home. J Vis Exp, (213). (Read full publication)
    16. Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA (2024). Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies. Ther Adv Musculoskelet Dis, 16, 1759720X241288071. (Read full publication)
    17. Navarro-Compn V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A (2024). Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. J Rheumatol, 52(1), 23-32. (Read full publication)
    18. Patel S, Walsh J, Pinnell D, Pei S, Chen W, Rojas J, Rathod A, Johnson J, Gawron A, Curtis JR, Baker JF, Cannon GW, Wu D, Lai M, Sauer BC (2024). Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration. Medicine (Baltimore), 103(37), e39476. (Read full publication)
    19. Walsh JA, Lin I, Zhao R, Shiff NJ, Morrison L, Emond B, Yu LH, Schwartzbein S, Lefebvre P, Pilon D, Chakravarty SD, Mease P (2024). Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs Real World Outcomes, 11(3), 487-499.
    20. Deodhar A, Kivitz AJ, Magrey M, Walsh JA, Mease PJ, Greenwald M, Kianifard F, Elam C, Bommidi GM, Winseck A, Gensler LS (2024). A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. Rheumatology (Oxford), 64(4), 1864-1872. (Read full publication)
    21. Baraliakos X, Saffore CD, Collins EB, Parikh B, Ye X, Walsh JA (2024). Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria. Rheumatol Ther, 11(4), 989-999. (Read full publication)
    22. Nowell WB, Gavigan K, Garza K, OBeirne R, Safford M, George M, Ogdie A, Walsh JA, Danila MI, Venkatachalam S, Stradford L, Rivera E, Curtis JR (2024). Which Educational Topics and Smartphone App Functions Are Prioritized by US Patients With Rheumatic and Musculoskeletal Diseases? A Mixed-Methods Study. J Rheumatol, 51(9), 904-912. (Read full publication)
    23. Walsh JA, Pei S, Alexander S, Braaten T, Walker JH, Clewell J, Douglas KM, Penmetsa GK, Ye X, Breviu B, Cannon GW, Kunkel GA, Sauer BC (2024). Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Semin Arthritis Rheum, 66, 152436. (Read full publication)
    24. Carroll C, Aalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Measuring Psoriasis Severity at Home. J Vis Exp, (205). (Read full publication)
    25. Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh JA (2023). Responsiveness and Minimum Clinically Important Difference in Patient-Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res (Hoboken), 75(10), 2182-2189. (Read full publication)
    26. Walsh JA, Saffore CD, Collins EB, Ostor A (2023). Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis. Rheumatol Ther, 10(5), 1385-1398. (Read full publication)
    27. Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng BJ (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis Care Res (Hoboken), 76(3), 421-425. (Read full publication)
    28. Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D (2023). Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther, 10(4), 887-899. (Read full publication)
    29. Magrey M, Walsh JA, Flierl S, Howard RA, Calheiros RC, Wei D, Khan MA (2023). The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease. ACR Open Rheumatol, 5(5), 264-276. (Read full publication)
    30. Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh JA (2023). Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis Care Res (Hoboken), 75(10), 2182-2189. (Read full publication)
    31. Baraliakos X, Ranza R, str A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A (2023). Efficacy of upadacitinib on psoriatic arthritis with axial involvement defined by investigator assessment and pro-based criteria: results from two phase 3 studies . Arthritis Res Ther, 25(1), 56. (Read full publication)
    32. Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A (2023). Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. J Rheumatol, 50(2), 192-196.
    33. Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers in Axial Spondyloarthritis: Observational Studies From the Program to Understand the Longterm Outcomes in Spondyloarthritis Registry. Arthritis Rheumatol, 75(2), 232-241. (Read full publication)
    34. Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine, 90(3), 105534. (Read full publication)
    35. Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA (2022). Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. J Manag Care Spec Pharm, 29, 1-12. (Read full publication)
    36. Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A (2022). Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol, 49, 1221-1228. (Read full publication)
    37. Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J (2021). Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open, 8(2). (Read full publication)
    38. van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M (2022). Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther, 39(6), 2806-2819. (Read full publication)
    39. Gavigan K, Nowell WB, Hunter T, Curtis JR, Malatestinic WN, Bolce RJ, Lisse JR, Walsh J (2022). Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. Rheumatol Ther, 9(2), 663-677. (Read full publication)
    40. Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh J (2022). Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. Rheumatol Ther, 9(2), 735-751. (Read full publication)
    41. Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Calderon DMS, Kiltz U (2022). Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care Res (Hoboken), 74(3), 451-460. (Read full publication)
    42. Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119. (Read full publication)
    43. Nowell WB, Gavigan K, Hunter T, Bolce RJ, Lisse JR, Himelein C, Dubey S, Curtis JR, Walsh JA (2021). Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. Rheumatol Ther, 9, 509-520. (Read full publication)
    44. Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh J (2021). Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol, 40(12), 4933-4942. (Read full publication)
    45. Nowell WB, Gavigan K, Hunter T, Malatestinic WN, Bolce RJ, Lisse JR, Himelein C, Curtis JR, Walsh JA (2021). Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR Open Rheumatol, 4, 85-94. (Read full publication)
    46. Bekele DI, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh JA, Clegg DO, Dubreuil M, Kaushik P, Ng B, Chang E, Duong R, Park J, Kerr GS (2021). Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int, 42, 1925-1937. (Read full publication)
    47. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. J Rheumatol, 48(10), 1559-1565. (Read full publication)
    48. Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni ME (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clin Rheumatol, 40(9), 3667-3677. (Read full publication)
    49. Wan MT, Walsh JA, Craig ET, Husni ME, Scher JU, Reddy SM, Leung YY, Ogdie A (2020). A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. Rheumatology (Oxford), 60(5), 2307-2316. (Read full publication)
    50. Walsh JA, Pei S, Penmetsa GK, Overbury RS, Clegg DO, Sauer BC (2020). Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research. J Rheumatol, 48(5), 685-692. (Read full publication)
    51. Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty SD (2021). Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study. Adv Ther, 38(5), 2353-2364. (Read full publication)
    52. Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, Gensler LS, Hunter T, Carlier H, Dong Y, Li X, Bolce R, Strand V, Braun J (2020). Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. J Rheumatol, 48(2), 188-197. (Read full publication)
    53. Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Marcelino Sandoval Calderon D, Kiltz U (2020). Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. Arthritis Care Res (Hoboken), 74, 451-460. (Read full publication)
    54. Walsh JA, Wan MT, Willinger C, Husni ME, Scher JU, Reddy SM, Ogdie A (2019). Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. J Rheumatol, 47(10), 1496-1505. (Read full publication)
    55. Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD (2020). Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin, 36(7), 1245-1252. (Read full publication)
    56. Overbury RS, Pei S, Breviu B, Clegg DO, Walsh JA (2020). Obstructive sleep apnea and fatigue in patients with inflammatory arthritis taking TNF-inhibitors. Int J Clin Rheumtol, 15(3), 38.
    57. Dougados M, Wei JC, Landew R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups (2019). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis, 79(2), 176-185. (Read full publication)
    58. Walsh JA, Pei S, Penmetsa G, Hansen JL, Cannon GW, Clegg DO, Sauer BC (2019). Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods. J Rheumatol, 47(1), 42-49. (Read full publication)
    59. Deodhar A, Gensler LS, Magrey M, Walsh JA, Winseck A, Grant D, Mease PJ (2019). Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap. Rheumatol Ther, 6(4), 487-501. (Read full publication)
    60. Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228. (Read full publication)
    61. Farahi JM, Lynn D, Anand P, Walsh JA, Hashim M, Duong R, Dellavalle RP, Reimold A, Kerr GS, Richards JS, Chang E, Kaushik P, Dubreuil M, Caplan L (2019). A Prospective Cross-Sectional Analysis of Construct Validity for the PALMPASS, A Brief Patient-Reported Outcome Measure for Psoriasis. J Psoriasis Psoriatic Arthritis, 4(4), 186-191. (Read full publication)
    62. Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce R (2019). Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016. BMC Rheumatol, 3, 39. (Read full publication)
    63. Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H (2019). Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther, 6(3), 435-450. (Read full publication)
    64. Coit P, Kaushik P, Caplan L, Kerr G, Walsh JA, Dubreuil M, Reimold A, Sawalha A (2019). Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood. J Autoimmun, 102, 126-132.
    65. Braaten TJ, Zhang C, Presson AP, Breviu B, Clegg DO, Walsh JA (2019). Gender Differences in Psoriatic Arthritis with Fatigue, Pain, Function and Work Disability. J Psoriasis Psoriatic Arthritis, 4(4), 192-197.
    66. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken), 71(1), 2-29. (Read full publication)
    67. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol, 71(1), 5-32. (Read full publication)
    68. Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2018). Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol, 37(12), 3285-3296. (Read full publication)
    69. Walsh JA, Song X, Kim G, Park Y (2018). Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database. Rheumatol Ther, 5(2), 463-474. (Read full publication)
    70. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. J Cardiol Cardiovasc Sci, 2(6), 17-23.
    71. Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski A (2018). The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl), 8, 65-74. (Read full publication)
    72. Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, Sauer BC (2018). Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC Musculoskelet Disord, 19(1), 317. (Read full publication)
    73. Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P (2018). Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses form an Administrative Claims Database . J Manag Care Spec Pharm, 24(7), 623-31. (Read full publication)
    74. Walsh JA, Arledge T, Nurminen T, Peterson L, Stark J (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. J Rheumatol, 45(7), 922-928. (Read full publication)
    75. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol, 37(7), 1869-1878. (Read full publication)
    76. Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm Health Serv Res, 9(2), 115-121. (Read full publication)
    77. Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gmez-Reino JJ, Aelion JA, ACTIVE investigators (2018). Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis, 77(5), 690-698. (Read full publication)
    78. Walsh JA, Adejoro O, Chastek B, Park Y (2017). Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res, 7(4), 369-380. (Read full publication)
    79. Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, Sauer BC (2017). Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. J Rheumatol, 45(3), 430-436. (Read full publication)
    80. Walsh JA, Tan H, Valdez H, Callis Duffin K (2017). Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity. J Psoriasis Psoriatic Arthritis, 2(4), 113-118.
    81. van der Heijde D, Dougados M, Landew R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A (2017). Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford), 56(9), 1498-1509. (Read full publication)
    82. Walsh JA, Shao Y, Leng J, He T, Teng CC, Redd D, Treitler Zeng Q, Burningham Z, Clegg DO, Sauer BC (2017). Identifying Axial Spondyloarthritis in Electronic Medical Records of US Veterans. Arthritis Care Res (Hoboken), 69(9), 1414-1420. (Read full publication)
    83. Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW (2016). Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ, 19(1), 34-43. (Read full publication)
    84. Walsh JA, Zhou X, Clegg DO, Teng C, Cannon GW, Sauer B (2015). Mortality in American Veterans with the HLA-B27 gene. J Rheumatol, 42(4), 638-44. (Read full publication)
    85. Sieper J, Landew R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP (2014). Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol, 67(3), 668-77. (Read full publication)
    86. Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS (2013). Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care Res (Hoboken), 66(9), 1410-6. (Read full publication)
    87. Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO (2014). Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol, 41(8), 1670-4. (Read full publication)
    88. Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, Gelfand JM, Krueger GG, Duffin KC (2013). Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol, 69(6), 931-7. (Read full publication)
    89. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2012). The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis, 72(6), 986-91. (Read full publication)
    90. Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol, 40(3), 287-93. (Read full publication)
    91. Walsh JA, Duffin KC, Crim J, Clegg DO (2012). Lower frequency of obstructive sleep apnea in spondyloarthritis patients taking TNF-inhibitors. J Clin Sleep Med, 8(6), 643-8. (Read full publication)
    92. Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF (1999). Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol, 43(4), 269-76. (Read full publication)

    Review

    1. Walsh JA, Magrey M (2020). Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. [Review]. J Clin Rheumatol, 27(8), e547-e560. (Read full publication)
    2. Magrey MN, Danve AS, Ermann J, Walsh JA (2020). Recognizing Axial Spondyloarthritis: A Guide for Primary Care. [Review]. Mayo Clin Proc, 95(11), 2499-2508. (Read full publication)
    3. Walsh JA, Rozycki M, Yi E, Park Y (2019). Application of machine learning in the diagnosis of axial spondyloarthritis. [Review]. Curr Opin Rheumatol, 31(4), 362-367. (Read full publication)
    4. Walsh JA, Song X, Kim G, Park Y (3/24/2019). Counting the Costs of Ankylosing Spondylitis. [Review]. Research Outreach, 2517(106), 82-85.
    5. Boehncke WH, Qureshi A, Merola JF, Thai D, Krueger GG, Walsh J, Kim N, Gottlieb AB (2013). Diagnosing and treating psoriatic arthritis: an update. [Review]. Br J Dermatol, 170(4), 772-86. (Read full publication)

    Conference Proceedings

    1. Haberman R, Perez-Chada LM, Siegel E, Reginato AM, Webster D, Chandran V, Walsh J, Rosen CF, Reddy S, Ogdie A, Scher JU, Merola JF (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. In Haberman R|Perez-Chada LM|Siegel E|Reginato AM|Webster D|Chandran V|Walsh J|Rosen CF|Reddy S|Ogdie A|Scher JU|Merola JF (Ed.), Rheumatol Int, 5(2), 68-72. (Read full publication)

    Case Report

    1. Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K (2015). Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. Br J Dermatol, 173(1), 272-4. (Read full publication)
    2. Kinard KWalsh JAPenmetsa GKWarner JEA (2014). Adalimumab and non-arteritic anterior ischaemic optic neuropathy: A case report. Neuroophthalmology, 38(5), 272-277. (Read full publication)

    Abstract

    1. Hernandez C, Schlesinger N, Rojas J, Walsh J, Braaten T, Kunkel G, Jones M, brian S, Facelli J, Cannon g, Lebiedz-Odrobina D (). The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans [Abstract]. 76(Suppl 9).
    2. Ostor A, Walsh J, Saffore C, Ye X, Patel M, Biljan A, Vora J, Truman I, Edwards M, Milligan G, Tillett W (2025). Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe [Abstract]. 77(Suppl 9).
    3. Allsop V, Glasheen B, Khong S, Minjarez A, Morlan N, Roake K, Cannon g, Grant N, Walsh JA (2024). Education and Medication Access Needs in Rheumatology Patients Starting New Medications: Quality Improvement Data from a Pharmacist Intervention [abstract]. [Abstract]. 76(Suppl 9).
    4. Ogdie A, Middaugh N, Marchese M, Walsh J, Bello N, Lisse J, Kronbergs A, Grace E, Ngantcha M, Mease P (2024). Cycling to TNFi versus switching to IL17Ai after a first TNFi discontinuation among patients with PsA and axSpA: The CorEvitas PsA/SpA Registry [Abstract]. 76(Suppl 9).
    5. Mease P, Zhao R, Ferrante S, Shiff N, Srinivas P, Chakravarty S, Walsh J (2024). Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors [Abstract]. 76(Suppl 9).
    6. Alexander S, Pei S, Penmetsa G, Reddy S, Scher J, Ogdie A, Walsh JA (2024). Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Appropriateness of Rheumatology Referrals and Treatment Outcomes [Abstract]. 76(Suppl 9).
    7. Loftis C, Caplan L, Padilla Zepeda J, Mukooba N, Caplan M, Fang M, Stolyar L, Walsh J, Kerr G, Raychaudhuri S, Reimold A, Wong M (2024). Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis [Abstract]. 76(Suppl 9).
    8. OSullivan M, Cannon g, brian S, Rojas J, Kunkel G, Walsh J, Roul P, Patel s, Baker J, England B, Braaten T (2024). Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans [Abstract]. 76(Suppl 9).
    9. Walsh J, Merola J, Ritchlin C, Tanaka Y, Favalli E, McGonagle D, Thai D, Ink B, Bajracharya R, Coarse J, Tillett W (2024). Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies [Abstract]. 76(Suppl 9).
    10. Walsh J, Pei S, Penmetsa G, Alexander S, Ly N, Molano-Romero R, Conlon A, Bakewell C, Reddy S, Scher J, Ogdie A (2024). Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening [Abstract]. 76(Suppl 9).
    11. Tillett W, Gladman D, Gossec L, Eells J, Healy P, Ink B, Lyris N, Walsh J (2024). Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab [Abstract]. 76(Suppl 9).
    12. Kristensen LE, Coates L, Mease PJ, Merola JF, Gisondi P, Nash P, Orbai AM, Tillett W, Ink B, Bajracharya R, Taieb V, Lambert J, Willems D, Walsh JA (2023). Achievement of increasingly stringent clinical disease control criteria was associated with greater improvements in physical function, pain and fatigue in patients with active psoriatic arthritis: 52-week results from Be Optimal, a phase 3 randomised, placebo-controlled study [Abstract]. 82(Suppl 1), 1776.
    13. Gossec L, Cella D, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, Yndestad A, Dina O (2023). Time to improvement of fatigue in patients with ankylosing spondylitis in a study of tofacitinib [Abstract]. 81(Suppl 1), 401.
    14. Magrey M, Walsh JA, Flierl S, Calheiros R, Wei D, Khan MA (2023). The International Map of Axial Spondyloarthritis (IMAS): a US patient perspective on diagnosis and burden of disease [Abstract]. 81(Suppl 1), 1521.
    15. Penmetsa GK, Pei S, Sauer BC, Douglas K, Walker J, Clewell J, Feng B, Walsh JA (2021). Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing [Abstract]. 73(suppl 10).